Abstract:Background: Cancers, a group of multifactorial complex diseases, are generally caused by mutation of multiple genes or dysregulation of pathways. Identifying biomarkers that can characterize cancers would help to understand and diagnose cancers. Traditional computational methods that detect genes differentially expressed between cancer and normal samples fail to work due to small sample size and independent assumption among genes. On the other hand, genes work in concert to perform their functions. Therefore, it is expected that dysregulated pathways will serve as better biomarkers compared with single genes.Results: In this paper, we propose a novel approach to identify dysregulated pathways in cancer based on a pathway interaction network. Our contribution is three-fold. Firstly, we present a new method to construct pathway interaction network based on gene expression, protein-protein interactions and cellular pathways. Secondly, the identification of dysregulated pathways in cancer is treated as a feature selection problem, which is biologically reasonable and easy to interpret. Thirdly, the dysregulated pathways are identified as subnetworks from the pathway interaction networks, where the subnetworks characterize very well the functional dependency or crosstalk between pathways. The benchmarking results on several distinct cancer datasets demonstrate that our method can obtain more reliable and accurate results compared with existing state of the art methods. Further functional analysis and independent literature evidence also confirm that our identified potential pathogenic pathways are biologically reasonable, indicating the effectiveness of our method.Conclusions: Dysregulated pathways can serve as better biomarkers compared with single genes. In this work, by utilizing pathway interaction networks and gene expression data, we propose a novel approach that effectively identifies dysregulated pathways, which can not only be used as biomarkers to diagnose cancers but also serve as potential drug targets in the future.

psSubpathway: a software package for flexible identification of phenotype-specific subpathways in cancer progression

SubtypeDrug: a software package for prioritization of candidate cancer subtype-specific drugs

Identification of Common and Subtype-Specific Mutated Sub-Pathways for a Cancer.

Identification of Cancer Dysfunctional Subpathways by Integrating DNA Methylation, Copy Number Variation, and Gene-Expression Data

CNA2Subpathway: identification of dysregulated subpathway driven by copy number alterations in cancer

CBioProfiler: a web and standalone pipeline for cancer biomarker and subtype characterization

Identifying Disease Related Sub-Pathways for Analysis of Genome-Wide Association Studies

DRviaSPCN: a Software Package for Drug Repurposing in Cancer Via a Subpathway Crosstalk Network

DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies.

Pathformer: a Biological Pathway Informed Transformer for Disease Diagnosis and Prognosis Using Multi-Omics Data.

Sccancer: a Package for Automated Processing of Single-Cell RNA-seq Data in Cancer

iSubGen generates integrative disease subtypes by pairwise similarity assessment

Individualized pathway activity algorithm identifies oncogenic pathways in pan-cancer analysis

Cancer subtype classification and modeling by pathway attention and propagation

An Integrated Tool for Multi-Dimensional Cancer Research Utilizing Clinical Proteomic Tumor Analysis Consortium Data

Uncovering disease-related multicellular pathway modules on large-scale single-cell transcriptomes with scPAFA

Unveiling Novel Double-Negative Prostate Cancer Subtypes Through Single-Cell RNA Sequencing Analysis

Integrative pathway analysis with gene expression, miRNA, methylation and copy number variation for breast cancer subtypes

Identification, Modeling and Simulation of Key Pathways Underlying Certain Cancers

Identifying Dysregulated Pathways in Cancers from Pathway Interaction Networks

Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark